Patient P-01736

Synthetic patientNBL-101 · Day 119 · 25–34 · F · baseline S03Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

90%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S03
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 62 ME-01 recommended — Monitoring Escalation ME-01
Day 63 Patient accepted — Started ME-01 in the companion
Day 66 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

GI instability-6
Treatment adherence+5
Inflammatory activity-4
Toxicity-4

What helped?

Monitoring Escalation ME-01Day 62
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 74 and rising
- WearableSleep 5.4 h, below personal baseline
Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 70
- WearableHRV 38 ms, trending down
Autonomic recovery ↑65
- WearableResting HR 80 bpm
- Wearable2,676 steps/day
- WearableShort sleep window
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 35/100
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 51

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.9 · butyrate capacity 35/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 29 ms
Sleep: 5.4 h
Steps: 2,713
Resting HR: 80 bpm

Daily log: GI score 74, nutritional resilience 25, adherence 44.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01772	55%	S20	NP-02	no change	50
P-01572	53%	S14	GI-04	worsened	41
P-01463	52%	S14	NP-02	no change	41
P-01582	51%	S14	GI-04	no change	45
P-01728	51%	S14	SC-12	improved	41
P-01897	51%	S14	ME-01	improved	43
P-01440	50%	S12	GI-04	no change	51
P-01615	50%	S14	ME-01	improved	48
P-01841	49%	S14	—	—	48
P-01531	48%	S14	ME-01	improved	51
P-01721	48%	S14	—	—	37
P-01762	48%	S14	NP-02	no change	40